# Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct07299747/  
OnCo record `nct07299747` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.

## Summary

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors. ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 255 participants. Primary completion is estimated at 2027-12-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: VBC103. Registered primary measures: Incidence of dose-limiting toxicities (DLT) as defined in the protocol; Incidence of Serious Adverse Events.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07299747
- Phase: 1/2
- Setting: Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
- Sponsor: VelaVigo Bio Inc
- Enrolled: 255

## Notes

- ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 255 participants. Primary completion is estimated at 2027-12-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT07299747: https://clinicaltrials.gov/study/NCT07299747

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [TROP2](https://onco.cc/targets/trop2/)
- companies: [VelaVigo](https://onco.cc/companies/velavigo/)
- drugs: [VBC103](https://onco.cc/drugs/vbc103/)

---
JSON: https://onco.cc/api/v1/entities/nct07299747.json